Physician profile

Devin Midura

Bronx, NY

NPI 1629572565

$1,214.49

in general payments reported to CMS, 2019-2025

7 companies · $378 in 2025

The $378 reported for 2025 was more than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$309.41
Education$68.49

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Davol INC. $466.73 2020-2021
Polynovo North America LLC $309.41 2025 Novosorb Btm
Becton, Dickinson and Company $134.36 2022
Cardiovascular Systems INC. $112.23 2020
Medtronic, INC. $91.21 2022
Astrazeneca Pharmaceuticals LP $68.49 2025 Imfinzi
Convatec INC. $32.06 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Devin Midura

$1,214.49

in general payments reported 2019-2025

Years
2020-2025
Top company
Davol INC.
Context
The $378 reported for 2025 was more than what a typical provider received nationally.

https://glasscript.com/doctor/8806196/devin-midura

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.